BerGenBio – executive interview

Published on 11 March 2022

BerGenBio (BGBIO) is a clinical-stage biopharmaceutical company headquartered in Bergen, Norway with clinical development capabilities in Oxford, UK. It is a pioneer in AXL biology and is developing innovative drugs for aggressive diseases including immune-evasive, drug-resistant and metastatic cancers. Lead asset bemcentinib is being investigated for AML, NSCLC and COVID-19.

In this video, Martin Olin, BGBIO’s chief executive officer, provides an overview of the clinical activity for bemcentinib and outlines newsflow expected in the year ahead.

Share this with friends and colleagues